EGFR and non-small cell lung carcinoma: An increasing body of evidence indicates that the activation of common oncogenic drivers in NSCLC (such as EGFR, ALK, and KRAS) is correlated with the induction of PD-L1 and corresponding inhibitors will reduce PD-L1 expression in initial treatment16,23–25.